参考价	面议

生化试剂

MedChemExpress (M

CAS	19891-51-1	纯度	≥98.0%
分子量	364.39	分子式	C₁₉H₂₄O₇
供货周期	现货	货号	HY-N3216
应用领域	医疗卫生,化工,生物产业,制药/生物制药

Nagilactone B | MCENagilactone B is a </b>liver X receptor</b> (<b>LXR</b>) agonist.

详细介绍

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Nagilactone B

CAS No. : 19891-51-1

产品活性：Nagilactone B is a liver X receptor (LXR) agonist.

研究领域：Metabolic Enzyme/Protease | Vitamin D Related/Nuclear Receptor

作用靶点：LXR

结构分类：萜类 | 其他萜类

来源：植物 | 罗汉松科 | 竹柏

In Vitro: RAW264.7 cells are co-incubated with oxLDL (20 μg/mL) and Nagilactone B (0.02, 0.1, and 0.5 μM) for 24 h. Oil Red O (ORO) staining reveals significant lipid accumulation and foam cell formation in RAW264.7 cells following oxLDL treatment. Nagilactone B (NLB) significantly ameliorates intracellular lipid accumulation. ORO positive areas are reduced by 30.05±7.49 (P<0.01), 47.25±5.39 (P<0.001), and 48.65±7.44% (P<0.001) in Nagilactone B (0.02, 0.1, and 0.5 μM)-treated groups, respectively. The effects of Nagilactone B are evaluated ton cholesterol efflux. Nagilactone B (0.02, 0.1, and 0.5 μM) markedly promotes cholesterol efflux to extracellular apolipoprotein A-I (apoA-I) and high density lipoprotein (HDL) with maximal 5.72- (P<0.05) and 2.34-fold (P<0.01), respectively.

In Vivo: Nagilactone B (NLB) suppresses atherosclerosis in apoE^-/- mice by inducing ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) mediated cholesterol efflux in macrophages. Male apoE-deficient mice on C57BL/6J background receive Nagilactone B (10 and 30 mg/kg) for 12 weeks. Compared with the model group, Nagilactone B treatment (10 and 30 mg/kg) significantly reduces en face lesions of total aorta areas. Six-week-old male apoE^-/- mice on an HFD are randomized to receive Atorvastatin (10 mg/kg/day), Nagilactone B (10 and 30 mg/kg/day), or CMC-Na for 12 weeks. Mice on chow diet are administered CMC-Na as the normal diet control group. En face aortic lesion areas are evaluated with Sudan IV staining and lesion areas in the aortic sinus monitored via ORO staining. Atherosclerosis developes slowly in the normal diet group, whereas lesions in the HFD model group are significantly increased in en face aortas. Nagilactone B treatment (10 and 30 mg/kg/day) significantly reduces en face aortic lesions, compared with the HFD group by 54.96±10.06% (P<0.01), 71.50±15.37% (P<0.001) in both NLB (L) and NLB (H) groups. In particular, Nagilactone B markedly attenuates atherosclerotic plaque lesion areas in the aortic arch aorta, thoracic aorta, and abdominal aorta [P<0.01 in NLB (H) group].

相关产品：Rovazolac | SR9238 | Saikosaponin A | 27-Hydroxycholesterol | Gymnestrogenin | (20S)-Protopanaxatriol | FITC-GW3965 | LXRβ agonist-4 | RGX-104 | GSK3987 | 24(S)-Hydroxycholesterol | BMS-779788 | GSK2033 | XL041 | DMHCA | LXR antagonist 2 | SR9243 | AZ876 | T0901317 | LXRβ agonist-3 | GW3965 | Larsucosterol (trimethylamine) | LXR-623 | LXR agonist 2 | BE1218 | LXR agonist 1

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种*仅有化合物库，我们致力于为*科研客户提供前沿的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药 Patent 收录了MCE客户的科研成果；
•   专业团队跟踪新的制药及生命科学研究进展，为您提供*新的活性化合物；
•   与世界各大制药公司及*科研机构建立了长期的合作。